| Bioactivity | Brevilin A is an orally active STAT3/JAK inhibitor (STAT3 IC50= 10.6 µM). Brevilin A shows anti-tumor activity, anti-proliferative activity to cancer cells, and can induce apoptosis and autophagy[1][2]. | ||||||||||||
| Invitro | Brevilin A (1-20 µM; 24 h) inhibits STAT3 signaling in a dose dependent manner[1].Brevilin A (0-50 µM; 24-72 h) inhibits the proliferation of NPC cells[2].Brevilin A (10 µM; 24 and 48 h) induces DU145 and MDA-MB-468 apoptosis after 24 h treatment[1].Brevilin A (12.5 and 25 µM; 24 h) blocks STAT3 tyrosine 705 phosphorylation in A549R cells[1]. Cell Viability Assay[1] Cell Line: | ||||||||||||
| Name | Brevilin A | ||||||||||||
| CAS | 16503-32-5 | ||||||||||||
| Formula | C20H26O5 | ||||||||||||
| Molar Mass | 346.42 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
Brevilin A
CAS: 16503-32-5 F: C20H26O5 W: 346.42
Brevilin A is an orally active STAT3/JAK inhibitor (STAT3 IC50= 10.6 µM). Brevilin A shows anti-tumor activity, anti-p
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.